Proteon Therapeutics, Inc. (PRTO)
(Delayed Data from NSDQ)
$0.44 USD
+0.02 (5.56%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.43 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Protara Therapeutics, Inc. [PRTO]
Reports for Purchase
Showing records 1 - 13 ( 13 total )
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are discontinuing coverage of Proteon Therapeutics to better allocate resources within our coverage universe
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal PATENCY-2 to Report in March; Higher $4 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PATENCY-1 Results Published; PATENCY-2 Results in March Could Be a Major Catalyst; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Awaiting PATENCY-2 Results in 1Q19; P1 PAD Study on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Second Time''s a Charm for Proteon? Upgrading to Buy With $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PATENCY-2 Progress on Target for Late-2019 Filing; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PATENCY-2 Nearing Full Enrollment; Higher $2.30 PT; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PATENCY-2 Enrollment On Track; Lowering PT to $1.70 on Dilution; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Patency-2 to Report in 2019; Vonapanitase Nabs Breakthrough Tag; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Patency-2 Amended But Lack of Catalyst Creates a Show- Me Situation; Downgrade to Neutral With a $3.00 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 PATENCY-1 Study to Readout in December; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
|